跳至主要内容
临床试验/EUCTR2021-005319-30-IT
EUCTR2021-005319-30-IT招募中1 期

A phase 3b, open-label, multi-country, multi-centre, long-term follow-up study of ZOSTER-049 (follow-up of ZOSTER-006/022 studies) to assess the prophylactic efficacy, safety and persistence of immune response of a Herpes Zoster subunit vaccine and assessment of persistence of immune response and safety of 1 or 2 additional doses administered in ZOSTER-049 in 2 subgroups of older adults - ZOSTER-101

GLAXOSMITHKLINE BIOLOGICALS0 个研究点目标入组 3,662 人开始时间: 2022年9月6日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
招募中
入组人数
3,662

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • Participants and participant’s caregiver, who, in the opinion of the investigator, can and are willing to comply with the requirements of the protocol.
  • Written or witnessed/thumb printed informed consent obtained from the participant of the participant prior to performance of any study-specific procedure.
  • Medically stable participants as established by medical history and clinical examination before entering into the study.
  • Participants who completed ZOSTER-049 study (following at least 1 dose of HZ/su in ZOSTER-006/022 studies).
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 1356
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 2306

排除标准

  • Medical conditions
  • Any clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study.
  • Prior/Concomitant therapy
  • Use of any investigational or non-registered product (drug, vaccine or medical device) for the treatment of HZ or Varicella Zoster Virus (VZV) infection at the time of enrolment or their planned use during the study period.
  • Previous vaccination against VZV or HZ and/or planned administration during the study of a VZV or HZ vaccine (including an investigational or non-registered vaccine other than HZ/su administered in studies ZOSTER-006/022 or ZOSTER-049).
  • Prior/Concurrent clinical study experience
  • Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug/invasive medical device) for the prevention and/or treatment of HZ or VZV and which may have a possible activity against VZV.

研究者

相似试验

进行中(未招募)
1 期
A study on the long-term efficacy, safety and persistence of immune response of a vaccine against Herpes Zoster in older adults
EUCTR2021-005319-30-DEGlaxoSmithKline Biologicals5,302
进行中(未招募)
4 期
A study on the long-term efficacy, safety and persistence of immune response of a vaccine against Herpes Zoster in older adultsHerpes zoster (Shingles) disease.
JPRN-jRCT2071220038Ogawa Masayuki129
进行中(未招募)
1 期
A study on the long-term efficacy, safety and persistence of immune response of a vaccine against Herpes Zoster in older adults
EUCTR2021-005319-30-FIGlaxoSmithKline Biologicals3,662
进行中(未招募)
1 期
A study on the long-term efficacy, safety and persistence of immune response of a vaccine against Herpes Zoster in older adults.Herpes Zoster
CTIS2023-505255-51-00GlaxoSmithKline Biologicals3,571
进行中(未招募)
1 期
A study on the long-term efficacy, safety and persistence of immune response of a vaccine against Herpes Zoster in older adultsVaccination against HZ and its related complications in adults older than 50 years (at the time of primary vaccination).MedDRA version: 20.0Level: PTClassification code 10019974Term: Herpes zosterSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 21.1Level: PTClassification code 10036376Term: Post herpetic neuralgiaSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.1Level: PTClassification code 10030865Term: Ophthalmic herpes zosterSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: PTClassification code 10063491Term: Herpes zoster oticusSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 21.1Level: PTClassification code 10075611Term: Varicella zoster virus infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: PTClassification code 10074297Term: Herpes zoster cutaneous disseminatedSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 23.1Level: PTClassification code 10080516Term: Herpes zoster reactivationSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 23.1Level: PTClassification code 10084396Term: Disseminated varicella zoster virus infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: PTClassification code 10072210Term: Genital herpes zosterSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.1Level: PTClassification code 10061208Term: Herpes zoster infection neurologicalSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: PTClassification code 10074259Term: Herpes zoster meningitisSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: PTClassification code 10074248Term: Herpes zoster meningoencephalitisSystem Organ Class: 10021881 - Infect
EUCTR2021-005319-30-ESGlaxoSmithKline Biologicals3,662